Scribe Therapeutics Inc. is a clinical-stage biotechnology company engineering purpose-built in vivo CRISPR technologies for disease prevention and durable therapeutic intervention. The company focuses on cardiovascular and metabolic diseases, with initial programs addressing the key drivers of atherosclerotic cardiovascular disease. Scribe designs CRISPR-based genetic medicines intended to be well-tolerated, effective, and durable, shifting the treatment paradigm from symptom-driven intervention to population-level prevention. The company was founded by CRISPR pioneers from the University of California, Berkeley, including co-founders Jennifer Doudna, Benjamin L. Oakes, David F. Savage, and Brett Staahl. Its scientific foundation involves modifying natural CRISPR systems to enhance specificity and potency for broad clinical application.

Summarised from the company's own disclosures, fiscal year ended Oct 2026

Industry Biotechnology Homepage investors.scribetx.com
Sector Healthcare IR page investors.scribetx.com
Tags
crispr, gene editing, cardiometabolic disease, in vivo therapy, genetic medicine, atherosclerotic cardiovascular disease
Press page —

Metrics

Valuation  
Market cap —
Market cap (USD) —
P/E —
PEG —
P/BV —
P/S —
P/OCF —
P/FCF —
Dividend yield —
Turnover / mcap —
Returns  
ROE —
ROI —
ROIC —
Profit margin —
Growth  
Revenue growing —
Profits growing —
Revenue up 3y —
Revenue up 5y —
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable —
Margin expanding —
Buying back stock —
Diluting (TTM) —
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 28
Quality score —
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure Q3 2026 Q2 2026
Revenue 1.636M 1.918M
Net profit -9.863M -6.477M
Free cash flow -11.264M —

Figure Q3 2026 Q2 2026
Share price 18.41 —
P/FCF -7.74 —

Filed figures

Figure Dec 2024 Dec 2025
Balance sheet detail
Lease liabilities (USD) — 6.09M
Cash and deposits (USD) 13.3M 12.8M
Right-of-use assets (USD) — 3.06M
Reported Sep 2, 2026 Sep 2, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

and Recent Corporate Highlights

Listed on the Nasdaq Global Market under the ticker symbol “SCTX,” and raised capital to fund the initial clinical development of STX-1150, STX-1200, and STX-1400

Continued enrollment in first-in-human Phase 1 clinical trial of STX-1150, the Company’s epigenetic silencing therapy for LDL-C lowering, with initial clinical data expected in the first half of 2027

Expanded strategic collaboration with Sanofi, providing access to the Company’s ELXR silencing technology and further validating its platform innovation

Reinforced leadership in genetic medicines through presentations and a new publication highlighting advances across the Company’s cardiovascular pipeline and proprietary epigenetic silencing and gene-editing technologies

Cash, cash equivalents, and marketable securities of $174.2 million as of September 30, 2026, provide funding into the first half of 2029

ALAMEDA, Calif., November 12, 2026 – Scribe Therapeutics Inc.

Scribe → Another proof point from CIRM-supported research Bull 0 Bear 0 Not a release

Scribe Therapeutics

LinkedIn Twitter or X

Menu

Close

Another proof point from CIRM-supported research

California Institute for Regenerative Medicine

|

October 7, 2026

1 min read

California Institute for Regenerative Medicine

|

October 7, 2026

Share on Social

share on Twitter or X

share on Linkedin

share onFacebook

share on Bluesky

More like this

[Media
\

Can Geneticists Fight Disease by Targeting ‘Nurture’ Instead of ‘Nature’?\

\

September 8, 2026\

\

The New York Times\


Read Now](https://www.nytimes.com/2026/09/08/science/epigenetic-editing.html) [

Press
\

Can Geneticists Fight Disease by Targeting ‘Nurture’ Instead of ‘Nature’?\

\

September 8, 2026\

\

The New York Times\


Read Now](https://www.scribetx.com/newsroom/can-geneticists-fight-disease-by-targeting-nurture-instead-of-nature)

[Media
\

Scribe Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights\

\

September 2, 2026\


Read Now](https://www.scribetx.com/newsroom/another-proof-point-from-cirm-supported-research#) [

Press
\

Scribe Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights\

\

September 2, 2026\


Read Now](https://www.scribetx.com/newsroom/scribe-therapeutics-reports-second-quarter-2026-financial-results-and-recent-corporate-highlights)

[Media
\

Scribe Therapeutics to Participate in Upcoming Investor Conferences\

\

September 1, 2026\


Read Now](https://www.scribetx.com/newsroom/another-proof-point-from-cirm-supported-research#) [

Press
\

Scribe Therapeutics to Participate in Upcoming Investor Conferences\

\

September 1, 2026\


Read Now](https://www.scribetx.com/newsroom/scribe-therapeutics-to-participate-in-upcoming-investor-conferences-2)

See More

Sign up to receive the latest updates

Thank you! Your submission has been received!

Oops! Something went wrong while submitting the form.

LinkedIn Twitter or X

©Scribe 2026

Privacy Policy Site by Bunsen

Scribe Therapeutics

LinkedIn Twitter or X

Menu

Close

Can Geneticists Fight Disease by Targeting ‘Nurture’ Instead of ‘Nature’?

The New York Times

|

September 8, 2026

1 min read

The New York Times

|

September 8, 2026

Share on Social

share on Twitter or X

share on Linkedin

share onFacebook

share on Bluesky

More like this

[Media
\

Another proof point from CIRM-supported research\

\

October 7, 2026\

\

California Institute for Regenerative Medicine\


Read Now](https://blog.cirm.ca.gov/research-and-science/another-proof-point-from-cirm-supported-research/) [

Press
\

Another proof point from CIRM-supported research\

\

October 7, 2026\

\

California Institute for Regenerative Medicine\


Read Now](https://www.scribetx.com/newsroom/another-proof-point-from-cirm-supported-research)

[Media
\

Scribe Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights\

\

September 2, 2026\


Read Now](https://www.scribetx.com/newsroom/can-geneticists-fight-disease-by-targeting-nurture-instead-of-nature#) [

Press
\

Scribe Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights\

\

September 2, 2026\


Read Now](https://www.scribetx.com/newsroom/scribe-therapeutics-reports-second-quarter-2026-financial-results-and-recent-corporate-highlights)

[Media
\

Scribe Therapeutics to Participate in Upcoming Investor Conferences\

\

September 1, 2026\


Read Now](https://www.scribetx.com/newsroom/can-geneticists-fight-disease-by-targeting-nurture-instead-of-nature#) [

Press
\

Scribe Therapeutics to Participate in Upcoming Investor Conferences\

\

September 1, 2026\


Read Now](https://www.scribetx.com/newsroom/scribe-therapeutics-to-participate-in-upcoming-investor-conferences-2)

See More

Sign up to receive the latest updates

Thank you! Your submission has been received!

Oops! Something went wrong while submitting the form.

LinkedIn Twitter or X

©Scribe 2026

Privacy Policy Site by Bunsen

Prompts

Scribe Therapeutics Inc. (ticker SCTX), listed in United States.

ETFs Holding Scribe Therapeutics Inc.

ETF Weight in ETF Shares Market value As of
ARKG 1.38% 1,597,118 $ 25.187M Nov 18, 2026